Discovery of 4-sulfamoyl-phenyl-β-lactams as a new class of potent carbonic anhydrase isoforms I, II, IV and VII inhibitors: The first example of subnanomolar CA IV inhibitors

详细信息    查看全文

• 作者：Srinivas Angapelly^a ; P.V. Sri Ramya^a ; Andrea Angeli^b ; Simona Maria Monti^c ; Martina Buonanno^c ; Mallika Alvala^d ; Cladiu T. Supuran^b ; ^{claudiu.supuran@unifi.it} ; Mohammed Arifuddin^a ; ^{arif@niperhyd.ac.in}
• 关键词：Carbonic anhydrase ; Sulfonamide ; β-Lactam ; Isoform CA I ; II ; IV ; VII
• 刊名：Bioorganic & Medicinal Chemistry
• 出版年：2017
• 出版时间：15 January 2017
• 年：2017
• 卷：25
• 期：2
• 页码：539-544
• 全文大小：433 K
• 卷排序：25

文摘

A series of benzenesulfonamides incorporating 1,3,4-trisubstituted-β-lactam moieties was prepared from sulfanilamide Schiff bases and in situ obtained ketenes, by using the Staudinger cycloaddition reaction. The new compounds were assayed as inhibitors of four human isoforms of the metalloenzyme carbonic anhydrase (hCA, EC 4.2.1.1) involved in various physiological/pathological conditions, hCA I, II, IV and VII. Excellent inhibitory activity was observed against all these isoforms, as follows: hCA I, involved in some eye diseases was inhibited with KIs in the range of 7.3–917 nM; hCA II, an antiglaucoma drug target, with KIs in the range of 0.76–163 nM. hCA IV, an isoform involved in several pathological conditions such as glaucoma, retinitis pigmentosa and edema was potently inhibited by the lactam-sulfonamides, with KIs in the range of 0.53–51.0 nM, whereas hCA VII, a recently validated anti-neuropathic pain target was the most inhibited isoform by these derivatives, with KIs in the range of 0.68–9.1 nM. The structure-activity relationship for inhibiting these CAs with the new lactam-sulfonamides is discussed in detail.